Clinical Trials Logo

Metastatic Cancer clinical trials

View clinical trials related to Metastatic Cancer.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05240040 Enrolling by invitation - Metastatic Cancer Clinical Trials

Treat Primary and Metastatic Liver Tumors

Start date: April 26, 2016
Phase:
Study type: Observational

The use of Radiospheres in the management of intrahepatic cholangiocarcinoma is largely unknown and not reported in the medical literature. Methodist Dallas Medical Center has a large volume of IR procedures with Radioembolization and the investigators feel it is imperative to understand the outcomes, risks and benefits of the therapy in order to formulate recommendation to other centers.

NCT ID: NCT04710290 Enrolling by invitation - Metastatic Cancer Clinical Trials

A Cohort Study of Beta-Glucan or Beta-Glucan Compound in Metastatic Cancers

Start date: January 4, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Immunity of cancer patients is an important issue. According to cancer immunity, it can be divided into three phases: clearance phase, equilibrium phase, and escape phase (cancer cells can avoid the recognition of immune cells). Βeta-glucans is extracted from yeast, it can increase immune function and drive of hematopoietic stem cells in animals and clinical trials. Glutamine can increase the repair of oral and intestinal mucosa of patients receiving chemical and radiation therapy and can increase the lymphocytes of patients. Colostrum contains IgA, IgG, IgM, etc., known to protect the baby Cancer patients who are infected with intestinal bacteria and undergo systemic chemotherapy are less immune than normal adults. Investigators will compare β-glucan, glutamine, and colostrum immunoglobulin powder with β-glucan and control group, each group has 30 people, and observe the side effects and blood of patients under standard chemotherapy. The performance of the immune system, such as helpers and cytotoxic T cells and NK cells, and to observe the differences in treatment interruption or delay rates and treatment rates.

NCT ID: NCT00068003 Enrolling by invitation - Breast Cancer Clinical Trials

Harvesting Cells for Experimental Cancer Treatments

Start date: September 8, 2003
Phase:
Study type: Observational

Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will collect white blood cells from normal volunteers and white blood cells and/or tumor cells, from patients who have been screened for and are eligible for a NCI Surgery Branch treatment protocol. The cells collected from normal volunteers will be used as growth factors for the cells during the period of laboratory growth. The cells and/or tumor from patients will be used to make the cell treatment product. Eligibility: Patients must be eligible for a NCI Surgery Branch Treatment Protocol Normal Volunteers must meet the criteria for blood donation Design Both patients and normal Volunteers will undergo apheresis. Patients will then undergo further testing as required by the treatment protocol. There is no required follow up for normal volunteers.